The Anti-Migraine Market 2007-2022

Table of Contents

Chapter 1 Executive Summary

Chapter 2 Introduction

• 2.1 What are Migraines
  • 2.1.1 What Causes Migraine?
  • 2.1.2 Symptom Phases of Migraine
    • 2.1.2.1 Prodrome Phase
    • 2.1.2.2 Auras Phase
    • 2.1.2.3 Attack Phase
    • 2.1.2.4 Postdrome Phase
• 2.2 What is Headache Pain?
  • 2.2.1 Tension Headaches
  • 2.2.2 Cluster Headaches
• 2.3 Which Drugs are Approved for Migraine Treatment?
  • 2.3.1 Acute Symptomatic Relief of Migraine Pain
    • 2.3.1.1 What are the Triptans?
      • 2.3.1.1.1 Sumatriptan (Imitrex, Imigran, Imigran Recovery)
      • 2.3.1.1.2 Rizatriptan (Maxalt)
      • 2.3.1.1.3 Zolmitriptan (Zomig)
      • 2.3.1.1.4 Eletriptan (Relpax)
      • 2.3.1.1.5 Naratriptan (Naramig)
      • 2.3.1.1.6 Almotriptan (Axert, Almogran)
      • 2.3.1.1.7 Frovatriptan (Frova)
    • 2.3.1.2 Which Ergots have the FDA Approved for Migraine Treatment?
      • 2.3.1.2.1 Side Effects of Ergots
      • 2.3.1.2.2 Withdrawal of Drug
    • 2.3.1.3 Which Analgesics Have the FDA Approved for Migraine Treatment?
    • 2.3.1.4 Which Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Have Been Approved by the FDA?
• 2.4 Opioids on the Market
• 2.5 Beta Blockers on the Market
• 2.6 Anticonvulsants for Migraine (Depakote and Topamax)
• 2.7 Antidepressants
• 2.8 Calcium-Channel Blockers
• 2.9 Other Drug Classes Under Investigation

Chapter 3 The Global Anti-Migraine Market

• 3.1 The Global Anti-Migraine Market Analysis
  • 3.1.1 GSK' s Blockbuster Migraine Drug Imitrex Faces Loss of Sales
    • 3.1.1.1 GSK Waiting Approval for New Potential Anti-Migraine Blockbuster Drug
  • 3.1.2 AstraZeneca' s Zomig - The New Market Leader Perhaps?
  • 3.1.3 Relpax Shows Positive Growth
  • 3.1.4 What Does the Future Hold for Migraine Therapy?
  • 3.1.5 What are the Unmet Needs in the Management of Migraine?
  • 3.1.6 Visiongain Believes That Significant Advances Will Occur in this Market with Potentially High Revenues for Next-Generation Products
  • 3.1.7 GSK Currently Leads the Anti-Migraine Market
  • 3.1.8 Imitrex will be Overtaken by Zomig as the Leading Anti-Migraine Product
  • 3.1.9 The Top Ten Countries in the Anti-Migraine Market

Chapter 4 Forces Affecting the Anti-Migraine Market

• 4.1 SWOT Analysis of the Anti-Migraine Market
  • 4.1.1 Market Drivers
  • 4.1.2 Market Restraints
  • 4.1.3 Why Growth in the Market is Expected?
• 4.2 Success of the Triptan Drugs
  • 4.2.1 Niche Markets and the Success of the Triptan
  • 4.2.2 What are the Therapeutic Advantages Offered by the Newer Triptans?
  • 4.2.3 Will a Single Triptan Reign Supreme?
• 4.3 Lack of Adequate Reimbursement Limits Potential of Anti-Migraine Drugs
• 4.4 Choosing the Right Medication
• 4.5 Patient Problems with Anti-Migraine drugs
• 4.6 What are the Costs of Migraine to the US?
  • 4.6.1 Cost of Migraine
  • 4.6.2 How much Does Migraine Cost the US in Terms of Medical, Missed Workdays and Lost Productivity?
• 4.7 FDA Reject Endo' s Attempt to Expand the Label for Frova
• 4.8 Complications of the Triptans

Chapter 5 The Prevalence of Migraine

• 5.1 What is the Global Prevalence of Migraine?
  • 5.1.1 Why Will the Prevalence of Migraine Increase?
• 5.2 Prevalence of Migraine in the US
• 5.3 What are the Affects of Migraine on Specific Populations?
  • 5.3.1 Prevalence by Gender
    • 5.3.1.1 Menstrual Migraine
    • 5.3.1.2 Pregnancy and Migraine
  • 5.3.2 Prevalence by Age
    • 5.3.2.1 Migraine in Children
    • 5.3.2.2 Migraine in Later Life

Chapter 6 Pipeline Developments

• 6.1 Agents in Phase II of Clinical Development
  • 6.1.1 Addex' s ADX10059
  • 6.1.2 GSK' s 274150, 468816 and 705498
• 6.2 Agents in Phase III of Clinical Development
  • 6.2.1 Merck' s MK0974
  • 6.2.2 GSK' s 406381
• 6.3 Time is Running out for Pozen & GSK After the FDA Request More Clinical Data on Trexima
• 6.4 Pozen' s MT-100
• 6.5 Discussion of Current Pipeline Developments
• 6.6 Summary of Pipeline Products Phase II and Above

Chapter 7 Alternative Therapies

• 7.1 Acupuncture
• 7.2 Biofeedback
• 7.3 Butterbur Root
• 7.4 Chiropractic
• 7.5 CoQ10
• 7.6 Feverfew Leaf
• 7.7 Ginkgo
• 7.8 Glucosamine
• 7.9 Hormones
  • 7.9.1 Melatonin
  • 7.9.2 Estriol
• 7.10 Magnesium
• 7.11 NTI Tension Suppression System
• 7.12 Vitamin B2

Chapter 8 Conclusion

• 8.1 Migraine is a Serious Condition with High Prevalence
• 8.2 Migraine Market Analysis
  • 8.2.1 The Anti-Migraine Market Will Suffer From the Patent Expiry of its Leading Product
  • 8.2.2 How have Anti-Migraine Drugs Succeeded?
  • 8.2.3 How an Increase in Prevalence will affect Sales Growth
  • 8.2.4 Why is a Growth in the Market Expected?
  • 8.2.5 Niche Markets - Menstrual Migraine
  • 8.2.6 Market Drivers
  • 8.2.7 Market Restraints
• 8.3 Geographical Breakdown of Revenues in the Anti-Migraine Market
  • 8.3.1 Sales of Anti-Migraine Drugs Will Decrease in the US from 2007 to 2012
  • 8.3.2 France Will Have the Second-Highest Sales of Anti-Migraine Drugs
• 8.4 There are Promising Developments Currently in Mid to Late Stage Clinical Testing
• 8.5 Outlook for the Future of the Anti-Migraine Market

Appendix A: About Visiongain

Appendix B: Visiongain Report Evaluation Form

TABLES

• Table 2.1 FDA Approved Triptans for Migraine Treatment
• Table 2.2 FDA Approved Ergots for Migraine Treatment
• Table 2.3 FDA Approved Analgesics for Migraine Treatment
• Table 2.4 FDA Approved NSAIDs for Migraine Treatment
• Table 3.1 The World Anti-Migraine Market Forecast ($m), 2007-2022
• Table 3.2 Imitrex Forecast ($m), 2007-2012
• Table 3.3 Zomig Forecast ($m), 2007-2012
• Table 3.4 Relpax Forecast ($m), 2007-2012
• Table 3.5 Top 10 Leading Companies in the Anti-Migraine Market, Revenue and Market Share, 2006
• Table 3.6 Top Ten Countries in the Anti-Migraine Market Revenue ($m) Forecast 2007-2012
• Table 4.1 SWOT Analysis of the Anti-Migraine Market
• Table 4.2 Economic Burden of Migraine in the US
• Table 5.1 Lifetime Prevalence of Headaches among Gender
• Table 6.1 Summary of Pipeline Products Phase II and Above, 2007
• Table 8.1 Geographical Breakdown of Revenues in the Anti-Migraine Market ($m), 2006-2012

GRAPHS

• Graph 1.1 Top Anti-Migraine Products Revenue Forecast ($m), 2007-2012
• Graph 3.1 Anti-Migraine World Market Revenue Forecast ($m), 2007-2022
• Graph 3.2 Imitrex Revenue Forecast ($m), 2007-2012
• Graph 3.3 Zomig Revenue Forecast ($m), 2007-2012
• Graph 3.4 Relpax Revenue Forecast ($m), 2007-2012
• Graph 3.5 Top 10 Leading Companies in the Anti-Migraine Market ($m), 2006
• Graph 8.1 Total Sales of Anti-Migraine Drugs ($m), 2007-2022
• Graph 8.2 Sales of the Leading Anti-Migraine Drugs ($m), 2007-2012

CHARTS

• Chart 3.1 Leading Companies in the Anti-Migraine Market, Market Share (%), 2006
• Chart 3.2 Top Countries in the Anti-Migraine Market, Market Share (%), 2006
• Chart 3.3 Top Countries in the Anti-Migraine Market, Market Share (%), 2009
• Chart 3.4 Top Countries in the Anti-Migraine Market, Market Share (%), 2012

Companies Mentioned in this Report

• Abbott Laboratories
• Addex
• Alexza
• Almirall Prodesfarma
• Apothecon
• AstraZeneca
• Bayer
• Bedford
• Bristol-Myers Squibb
• CeNeS
• Dr. Reddy' s
• Elan
• Faust Pharmaceuticals
• FDA
• GD Searle
• Geneva Pharmaceuticals
• GSK
• Harvest Pharms
• Houston University
• J&J
• Lilly
• Menarini
• Merck & Co
• MHRA
• Novartis
• Odyssey Pharms
• Ortho-McNeil
• Pfizer
• Pharmacia
• Pozen
• Reckitt Benckiser
• Roche
• Roxro
• Sanofi
• UCB
• Vernalis
• Winston Laboratories
• Wyeth